ADMA Biologics (NASDAQ:ADMA) and Microbot Medical (NASDAQ:MBOT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, dividends and risk.
Volatility and Risk
ADMA Biologics has a beta of 2.84, indicating that its stock price is 184% more volatile than the S&P 500. Comparatively, Microbot Medical has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500.
This is a summary of current ratings and target prices for ADMA Biologics and Microbot Medical, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
ADMA Biologics currently has a consensus price target of $11.58, indicating a potential upside of 245.77%. Microbot Medical has a consensus price target of $1.75, indicating a potential downside of 27.08%. Given ADMA Biologics’ stronger consensus rating and higher possible upside, research analysts plainly believe ADMA Biologics is more favorable than Microbot Medical.
Valuation and Earnings
This table compares ADMA Biologics and Microbot Medical’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|ADMA Biologics||$22.76 million||6.82||-$43.75 million||($1.91)||-1.75|
|Microbot Medical||N/A||N/A||-$7.58 million||N/A||N/A|
Microbot Medical has lower revenue, but higher earnings than ADMA Biologics.
Insider and Institutional Ownership
57.5% of ADMA Biologics shares are owned by institutional investors. Comparatively, 4.1% of Microbot Medical shares are owned by institutional investors. 16.9% of ADMA Biologics shares are owned by company insiders. Comparatively, 20.3% of Microbot Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
This table compares ADMA Biologics and Microbot Medical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
ADMA Biologics beats Microbot Medical on 7 of the 11 factors compared between the two stocks.
ADMA Biologics Company Profile
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease. The company also operates source plasma collection facilities in Norcross and Marietta, Georgia. In Addition, the company offers Nabi-HB for the treatment of acute exposure; and Bivigam for the treatment of primary humoral immunodeficiency. It distributes its products through independent distributors, sales agents, specialty pharmacies, and others. The ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.
Microbot Medical Company Profile
Microbot Medical Inc., a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The company, through its ViRob and TipCAT micro-robotic technologies, is developing two product candidates, including the Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; and a self-propelling, semi-disposable endoscope, which is used in colonoscopy procedures. It also holds an intellectual property portfolio that comprises 9 patent families, which include 9 patents granted in the United States, 12 patents granted outside the United States, and 15 patent applications pending worldwide. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.